单纯输血与联合重组人促红素注射液对恶性血液病贫血患者预后及安全性的影响  

Effects of Blood Transfusion Alone Combined with Recombinant Human Erythropoietin Injection on the Prognosis and Safety of Patients with Anemia of Hematological Malignancy

作　　者：张林海 柴星星[2] 杨伏猛[3] 霍霓 李茜 王姗 ZHANG Linhai;CHAI Xingxing;YANG Fumeng;HUO Ni;LI Qian;WANG Shan(Dept.of Blood Transfusion,the Second People’s Hospital of Lianyungang,Jiangsu Lianyungang 222000,China;Dept.of Hematology,the Second People’s Hospital of Lianyungang,Jiangsu Lianyungang 222000,China;Dept.of Clinical Lab,the Second People’s Hospital of Lianyungang,Jiangsu Lianyungang 222000,China)

机构地区：[1]连云港市第二人民医院输血科,江苏连云港222000 [2]连云港市第二人民医院血液科,江苏连云港222000 [3]连云港市第二人民医院检验科,江苏连云港222000

出　　处：《中国医院用药评价与分析》2021年第4期455-458,共4页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的:探讨单纯输血与联合重组人促红素注射液对恶性血液病贫血患者预后及安全性的影响。方法:选取2010年8月至2019年8月连云港市第二人民医院收治的240例恶性血液病贫血患者为研究对象,根据非随机临床同期对照研究及患者自愿原则分为对照组(单纯输血治疗,n=120)、观察组(在对照组基础上联合重组人促红素注射液治疗,n=120)。观察两组患者血红蛋白(Hb)、网织红细胞百分比(RET)、血清铁(Fe)、临床疗效、预后[生活质量核心问卷(quality of life questionnaire-core 30,QLQ-C30)评分]及药物安全性。结果:与治疗前比较,两组患者治疗后Hb、RET及Fe水平明显升高,且观察组患者的升高幅度明显大于对照组,差异均有统计学意义(P<0.05)。观察组患者的总有效率为93.33%(112/120),明显高于对照组的83.33%(100/120),差异有统计学意义(χ^(2)=5.822,P<0.05)。观察组患者的平均治疗费用为(1003.51±125.64)元,明显低于对照组的(1306.25±131.66)元,差异有统计学意义(P<0.05)。治疗后1、3及5个月,观察组患者的QLQ-C30评分明显高于对照组,差异有统计学意义(P<0.05)。观察组患者的不良反应总发生率为28.33%(34/120),较对照组的41.67%(50/120)明显更低,差异有统计学意义(χ^(2)=4.689,P<0.05)。结论:与单纯输血比较,联合应用重组人促红素注射液治疗恶性血液病贫血患者的临床疗效、预后更佳,可更有效提高Hb、RET及Fe水平,且安全性更好。OBJECTIVE:To probe into the effect of blood transfusion alone combined with recombinant human erythropoietin injection on the prognosis and safety of patients with anemia of hematological malignancy.METHODS:240 patients with anemia of hematological malignancy admitted into the Second People’s Hospital of Lianyungang from Aug.2010 to Aug.2019 were selected as objects and divided into control group(treated with blood transfusion alone,120 cases)and observation group(treated with recombinant human erythropoietin injection on the basis of the control group,120 cases)according to the non-randomized clinical concurrent controlled study and the principle of patients’voluntariness.The hemoglobin(Hb),reticulocyte percentage(RET),serum iron(Fe),clinical efficacy,prognosis[quality of life questionnaire-core 30(QLQ-C30)score]and drug safety of the two groups were observed.RESULTS:Compared with before treatment,the Hb,RET and Fe levels of both groups had been significantly increased,and the observation group had significantly greater amplification then that of the control group,with statistically significant differences(P<0.05).The total effective rate of observation group was 93.33%(112/120),which was significantly higher than that of the control group(83.33%,100/120),with statistically significant difference(χ^(2)=5.822,P<0.05).The average treatment expense of observation group was(1003.51±125.64)yuan,which was significantly lower than that of the control group[(1306.25±131.66)yuan],with statistically significant difference(P<0.05).At 1,3 and 5 months after treatment,the QLQ-C30 score of observation group was significantly higher than that of the control group,with statistically significant difference(P<0.05).The incidence of adverse drug reactions of observation group was 28.33%(34/120),which was significantly lower than that of the control group(41.67%,50/120),with statistically significant difference(χ^(2)=4.689,P<0.05).CONCLUSIONS:Compared with blood transfusion alone,the recombinant human erythropoietin injecti

关 键 词：恶性血液病 贫血 单纯输血 重组人促红素注射液 预后 

分 类 号：R973[医药卫生—药品]